Children aged 6-12 with severe atopic dermatitis (AD) have very limited treatment options. The studies presented below demonstrate how effective and safe dupilumab, a monoclonal antibody targeting interleukins 4 and 13, is in their case. Since October, this medication is newly covered even for children from 6 years of age.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
